p. 4377−4384
2476-762X
Vol.15/No.11
p. 4385−4394
2476-762X
Vol.15/No.11
p. 4395−4403
2476-762X
Vol.15/No.11
p. 4405−4409
2476-762X
Vol.15/No.11
p. 4411−4416
2476-762X
Vol.15/No.11
p. 4417−4422
2476-762X
Vol.15/No.11
p. 4423−4428
2476-762X
Vol.15/No.11
p. 4429−4436
2476-762X
Vol.15/No.11
0.05). Although there was not any association between genotypes and disorder, CT was themost common genotype in this population. This genotype prevalence was also higher in the patients with wellgrade (54.9%) and colon (72.0%) tumors. Our results provide the first evidence that this polymorphism is not apotential contributor to the risk of colorectal cancer and clinicopathological features in an Iranian population,and suggests the need of a large-scale case-control study to validate our results.]]>
p. 4437−4441
2476-762X
Vol.15/No.11
p. 4443−4448
2476-762X
Vol.15/No.11
p. 4449−4454
2476-762X
Vol.15/No.11
p. 4455−4458
2476-762X
Vol.15/No.11
p. 4459−4463
2476-762X
Vol.15/No.11
p. 4465−4466
2476-762X
Vol.15/No.11
p. 4467−4474
2476-762X
Vol.15/No.11
p. 4475−4482
2476-762X
Vol.15/No.11
p. 4483−4486
2476-762X
Vol.15/No.11
p. 4487−4491
2476-762X
Vol.15/No.11
p. 4493−4497
2476-762X
Vol.15/No.11
p. 4499−4505
2476-762X
Vol.15/No.11
p. 4507−4511
2476-762X
Vol.15/No.11
p. 4513−4518
2476-762X
Vol.15/No.11
p. 4519−4525
2476-762X
Vol.15/No.11
p. 4527−4533
2476-762X
Vol.15/No.11
p. 4535−4538
2476-762X
Vol.15/No.11
B/Q>Q+B group, while the order of E-cadherin expression level was contrary,Q+B>Q/B>C group. Thus, Q/B, especially Q+B display reverse effect targeting both altered DNA methylationand histone acetylation, acting as histone deacetylase inhibitor mediated via epigenetic-NF-κB cascade signaling.]]>
p. 4539−4543
2476-762X
Vol.15/No.11
0.05), but HGF content showed significant difference (P<0.01). Compared withpre-operation, VEGF, SIL-2R and HGF contents 7 days and 1 month after PMCT all manifested significantdifferences (P<0.01). By comparison to 7 days with 1 month after PMCT, there was no statistical significanceregarding the VEGF content (P>0.05), whereas SIL-2R and HGF contents showed significant change (P<0.01).Conclusions: The contents of serum VEGF, SIL-2R and HGF have obviously dynamic changes in primary HCCbefore and after PMCT, and their joint detection is expected to be an effective hematologic evaluation index ofPMCT for primary HCC.]]>
p. 4545−4548
2476-762X
Vol.15/No.11
0.05). Overall success rate in the meropenem and PIP/TAZ groups were 92.4% and 91.9% respectively. Noserious adverse effects occurred in either of the groups. Conclusions: Meropenem and PIP/TAZ monotherapyare equally safe and effective in the initial treatment of febrile neutropenia in children with cancer.]]>
p. 4549−4553
2476-762X
Vol.15/No.11
p. 4555−4561
2476-762X
Vol.15/No.11
p. 4563−4566
2476-762X
Vol.15/No.11
p. 4567−4570
2476-762X
Vol.15/No.11
p. 4571−4573
2476-762X
Vol.15/No.11
p. 4575−4581
2476-762X
Vol.15/No.11
p. 4583−4587
2476-762X
Vol.15/No.11
p. 4589−4594
2476-762X
Vol.15/No.11
p. 4595−4599
2476-762X
Vol.15/No.11
p. 4601−4607
2476-762X
Vol.15/No.11
p. 4609−4615
2476-762X
Vol.15/No.11
p. 4617−4622
2476-762X
Vol.15/No.11
p. 4623−4627
2476-762X
Vol.15/No.11
p. 4629−4635
2476-762X
Vol.15/No.11
p. 4637−4642
2476-762X
Vol.15/No.11
p. 4643−4650
2476-762X
Vol.15/No.11
p. 4651−4657
2476-762X
Vol.15/No.11
0.05).However, the correlation between salivary and serum CA 15-3 concentration was positive and statisticallysignificant (r=0.27, p=0.03). In conclusion, the positive correlation between salivary and serum expression foundin our study suggests that saliva could be an alternative to blood sampling to help breast cancer monitoring.]]>
p. 4659−4662
2476-762X
Vol.15/No.11
p. 4663−4670
2476-762X
Vol.15/No.11
p. 4671−4676
2476-762X
Vol.15/No.11
p. 4677−4681
2476-762X
Vol.15/No.11
p. 4683−4688
2476-762X
Vol.15/No.11
p. 4689−4695
2476-762X
Vol.15/No.11
p. 4697−4703
2476-762X
Vol.15/No.11
p. 4705−4709
2476-762X
Vol.15/No.11
p. 4711−4716
2476-762X
Vol.15/No.11
p. 4717−4721
2476-762X
Vol.15/No.11
p. 4723−4726
2476-762X
Vol.15/No.11
p. 4727−4732
2476-762X
Vol.15/No.11
0.5 h infusion, on day 2, 3, 4; dexamethasone 40mg, 1h infusion, on day 1, 2, 3, 4 and 5; and methotrexate 12 mg, cytosine arabinoside 50 mg plus dexamethasone5 mg intrathecally, on day 2 and 7). Cycles were repeated every 3 weeks. After response assessment, patientsreceived whole brain radiotherapy. Results: Of the 8 PCNSL patients, 4 (50%) achieved CR and 3 (38%) PR, anoverall response rate of 88%. Four patients (50%) were in continuing remission at the end of this study after amedian follow-up of 30 months (range 10 to 56 months). Of the 8 SCNSL patients the overall response rate was63% (CR+PR: 38%+25%). All responses were achievable with predictable toxicity mainly reflecting reversiblemyelosuppression. Conclusion: This study suggests that FTD could be an effective treatment for CNS lymphoma,and is worthy of further evaluation.]]>
p. 4733−4738
2476-762X
Vol.15/No.11